Gemcitabine-Releasing TAR-200 System Receives FDA Approval for Bladder Cancer

What Is TAR-200 (Inlexzo)?

On September 9, 2025, the US Food and Drug Administration (FDA) approved a gemcitabine-releasing intravesical system for BCG-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) in adult patients, under the name Inlexzo (TAR-200) . Approval was based on notable findings reported in the SunRISe-1 trial, including an 82% Complete Response (CR) rate and, in half of patients, a Response Duration ≥12 months . It represents an important threshold in bladder-preserving treatment.

TAR-200 is an intravesical (placed inside the bladder), small ring/spiral (“pretzel”)-shaped device made from a biocompatible polymer—an implantable drug delivery system. The device is loaded with gemcitabine for release.

• When bladder fluid contacts the device, the polymer matrix releases gemcitabine in a controlled, continuous manner into the bladder.
• The drug diffuses directly into the bladder mucosa , creating a strong, sustained cytotoxic effect at the tumor site.
• Unlike conventional instillation, it provides a steady concentration over weeks of treatment.
• Minimal entry into the systemic circulation reduces toxicity and concentrates efficacy at the local site.

• Drug load: Per device: 225 mg gemcitabine.
• Dwell time: After each insertion, the device remains in the bladder for 3 weeks before removal.
• Induction: Every 3 weeks for a total of 6 months , comprising 8 administrations.
• Maintenance: Then every 12 weeks for up to 18 months (a total of 6 administrations), or until persistent/high-grade recurrence, progression or unacceptable toxicity occurs.

• CR (Complete Response) rate: Among 85 HR-NMIBC patients, 82.4% (95% CI: 72.6–89.8%) achieved CR.
• Response durability: Among those who achieved CR, 51–53%maintained their response for ≥12 months (according to the SunRISe-1 protocol, confirmed through central pathology ).
• Median Duration of Response (DOR): 25.8 months (95% CI: 8.3–not estimable).
• Bladder preservation: Among those who achieved CR, ~86%at 1 year were cystectomy-free at follow-up.
• Side effects (local): Mostly grade 1–2 dysuria and frequent urination.
• Serious adverse events: 12.9%; treatment discontinuation: 3.5%. No treatment-related deaths were reported.

🔹 Breakthrough Designation – December 2023

• Granted for BCG-unresponsive, high-risk CIS (+/− papillary tumor).

🔹 New Drug Application (NDA) – January 2025

• Submitted under the RTOR (Real-Time Oncology Review) program.

🔹 Priority Review – July 2025

• Instead of the standard 10 months, ~6 months was the target review time.

💧 Continuous, Controlled Release

• Releases gemcitabine at a constant rate over weeks and reduces “peak–trough” fluctuations.
• Prevents the rapid drug loss seen with conventional instillation.

📈 High Clinical Efficacy

• In SunRISe-1: 82% CR; in ≥50% of patients, CR lasted at least 12 months .
• Despite the noncomparative design, compared with existing intravesical options, the findings are noteworthy.

🛡 A Bladder-Preserving Approach

• In selected cases, the potential to reduce the need for cystectomy is important.
• In most patients who achieved CR, bladder preservation was achieved.

⚖️ Low Systemic Toxicity

• The drug’s local release keeps systemic exposure minimal.
• Side effects are mostly mild (grade 1–2) lower urinary tract symptoms.

🤝 Ease of Administration and Adherence

• Transurethral placement; fewer frequent hospital visits through 3-week cycles.
• Quality of life may be positively affected.

🔹 BCG-Unresponsive / Recurrent HR-NMIBC (CIS ± papillary)

• In this group, the standard approach is often radical cystectomy; TAR-200 offers a bladder-preserving alternative treatment.

🔹 Patients Unsuitable for / Unwilling to Undergo Cystectomy

• Patients avoiding surgery because of older age, comorbidities or preference.

🔹 High-Grade, Non-Muscle-Invasive Lesions

• Particularly for CIS or recurrent high-grade papillary tumors, SunRISe-1 data showed CR of 80%+ in patients.

• Bladder perforation risk makes treatment unsuitable.
• Delayed cystectomy and metastatic disease risk: pay attention to oncological timing in appropriate cases.
• MRI safety and embryo-fetal toxicity warnings are stated in the prescribing information.

With FDA approval, TAR-200 (Inlexzo), for patients with BCG-unresponsive HR-NMIBC + CIS, became a licensed intravesical option . High early CR rates and signs of durability may enable bladder preservation in selected patients. Its ultimate role will be determined by results from ongoing later-phase trials (SunRISe-2/-3).